Michael Fang

Jan 13, 2025 | nature.com | Michael Fang |David S. Knopman |Keenan A. Walker |Rebecca Gottesman |Elizabeth Selvin

AbstractUnderstanding the lifetime risk of dementia can inform public health planning and improve patient engagement in prevention. Using data from a community-based, prospective cohort study (n = 15,043; 26.9% Black race, 55.1% women and 30.8% with at least one apolipoprotein E4 (APOE ε4) allele), we estimated the lifetime risk of dementia (from age 55 years to 95 years), with mortality treated as a competing event.

Apr 4, 2024 | jamanetwork.com | Michael Fang |Dan Wang |Elizabeth Selvin |Linda A. DiMeglio

Prevalence of Type 1 Diabetes Among US Children and Adults by Age, Sex, Race, and Ethnicity Infections in Early Life and Development of Type 1 Diabetes Andreas Beyerlein, PhD; Ewan Donnachie, MSc; Sibille Jergens, MSc; Anette-Gabriele Ziegler, MD Maternal Type 1 Diabetes and Risk of Autism in Offspring Anny H. Xiang, PhD; Xinhui Wang, PhD; Mayra P. Martinez, MPH; Kathleen Page, MD; Thomas A. Buchanan, MD; R.

Dec 4, 2023 | acpjournals.org | Robert Centor |Michael Fang

In this episode of Annals On Call, Dr. Centor discusses the diagnosis of type 1 diabetes mellitus in adults with Dr. Michael Fang. Annals articles discussed include... Age at Diagnosis in U.S. Adults With Type 1 Diabetes: https://www.acpjournals.org/doi/10.7326/M23-1707About Annals On CallAnnals On Call focuses on a clinically influential article published in .

Sep 26, 2023 | acpjournals.org | Michael Fang |Dan Wang |Justin B. Echouffo-Tcheugui |Elizabeth Selvin

Background: Adult-onset type 1 diabetes is frequently misdiagnosed as type 2 diabetes, leading to inappropriate care (1). Emerging data suggest that up to 62% of type 1 diabetes cases develop after age 20 years (2). However, prior studies have been done in selected clinical populations. Clarifying the burden of adult-onset type 1 diabetes in the general population may help reduce misdiagnosis.

Sep 19, 2023 | acpjournals.org | Michael Fang |Justin B. Echouffo-Tcheugui |Elizabeth Selvin

IN RESPONSE: Glucagon-like peptide-1 receptor agonists and SGLT2 inhibitors may be important adjunct therapies for weight management in persons with T1DM. Our previous work has shown that approximately 5% of U.S. adults with T1DM receive a GLP-1 receptor agonist, and 3% receive an SGLT2 inhibitor (1). We believe at least 2 barriers may prevent greater uptake. The first barrier is safety.